Sequent Asset Management LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 1,751 shares of the company’s stock, valued at approximately $245,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares in the last quarter. BlackRock Inc. increased its position in Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Johnson & Johnson by 0.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock worth $4,757,593,000 after acquiring an additional 130,437 shares during the last quarter. FMR LLC grew its holdings in Johnson & Johnson by 5.9% during the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after acquiring an additional 1,509,745 shares during the last quarter. Finally, Capital World Investors grew its holdings in Johnson & Johnson by 4.1% during the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock worth $3,507,009,000 after acquiring an additional 1,050,000 shares during the last quarter. Institutional investors and hedge funds own 67.23% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of Johnson & Johnson stock opened at $131.76 on Tuesday. Johnson & Johnson has a twelve month low of $120.95 and a twelve month high of $148.32. The firm has a market capitalization of $350,440.66, a P/E ratio of 18.05, a PEG ratio of 2.08 and a beta of 0.74. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The company had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same period last year, the company posted $1.58 earnings per share. The firm’s revenue was up 11.5% compared to the same quarter last year. equities research analysts predict that Johnson & Johnson will post 8.11 EPS for the current year.

A number of equities research analysts have weighed in on JNJ shares. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Monday, April 9th. Jefferies Group set a $153.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Friday. Vetr lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 target price on the stock. in a report on Monday, March 26th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Monday, January 22nd. Finally, Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Five equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $144.03.

In other news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the sale, the vice president now directly owns 357,906 shares of the company’s stock, valued at $46,477,673.16. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.22% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.dailypolitical.com/2018/04/17/sequent-asset-management-llc-takes-245000-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.